A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects

Staphylococcus Aureus Clinical Trial

Official title:

A Phase 1, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Extended Half-Life Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin, in Healthy Adult Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01769417
• Other study ID #: CD-ID-MEDI4893-1133
• Status: Completed
• Phase: Phase 1
• First received: January 11, 2013
• Last updated: July 23, 2014
• Start date: January 2013
• Est. completion date: May 2014

Study information

• Verified date: July 2014
• Source: MedImmune LLC
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1, first time in human study enrolling approximately 33 healthy adult subjects (18-65 yrs) from one study site. The purpose of this study is to evaluate the safety, tolerability and PK of MEDI4893 in healthy adult volunteers administered as a single IV dose compared with placebo, across 4 cohorts. The 4 dose cohorts will enroll sequentially. Subjects will be followed for safety from the time of Informed Consent through 360 days post dose.

Description:

This is a phase 1, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability and pharmacokinetics of MEDI4893, an extended half-life human monoclonal antibody against Staphylococcus aureus alpha toxin, in healthy adult subjects. Approximately 33 subjects will be enrolled across 4 fixed dose cohorts at 1 study site . This study will last approximately 389 days, constituting a screening period of up to 28 days, 1 day of investigational product administration, and a 360 day safety follow up period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 85
• Est. completion date: May 2014
• Est. primary completion date: May 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Age 18 through 65 years at screening.

2. Written informed consent and any locally required authorization (eg, HIPAA) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.

3. Females of childbearing age using contraception for at least 28 days prior to receiving the dose of investigational product, and for 1 year after receiving IP.

4. Weight = 45 kg and = 110 kg at screening.

5. Healthy by medical history and physical examination at screening.

6. Systolic blood pressure (BP) < 140 mm Hg and diastolic BP < 90 mm Hg at screening.

7. Normal electrocardiogram (ECG) at screening.

8. Able to complete the 360-day postdose follow-up period as required by the protocol.

Exclusion Criteria:

1. Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.

2. Employees of the sponsor, clinical study site, or any other individuals involved with the conduct of the study, or immediate family members of such individuals.

3. Acute illness at study entry.

4. Fever 99.5F or higher on day of dosing.

5. Any drug therapy within 7 days prior to Day 1.

6. Blood donation in excess of 400 mL within 6 months prior to study entry.

7. Receipt of immunoglobulin or blood products within 6 months prior to study entry.

8. Receipt of any prior investigational drug or investigational vaccine within 120 days prior to investigational product dosing or planned dosing

9. Receipt of any standard vaccine within 14 days prior to investigational product dosing.

10. Previous receipt of a monoclonal antibody.

11. Receipt of immunosuppressive medications in the prior year or any active or prior history of immunodeficiency. Any course of systemic corticosteroids of more than 7 day duration during the prior year excludes a subject.

12. History of allergic disease or reactions likely to be exacerbated by any component of the investigational product.

13. Previous medical history or evidence of an intercurrent illness that may compromise the safety of the subject in the study.

14. Evidence of any systemic disease on physical examination at screening.

15. Evidence of infection (ie, positive laboratory test result) with hepatitis A, B, or C virus or human immunodeficiency virus (HIV) at screening.

16. Any of the following at screening:

1. Hemoglobin < 12.0 g/dL for males and < 11.5 g/dL for females.

2. WBC count < 3,800/mm3.

3. Platelet count < 140,000/mm3.

4. AST, ALT, BUN, serum creatinine > upper limit of normal (ULN).

5. Positive Urine Class A drug screen.

6. Other abnormal laboratory values in the screening panel, which in the opinion of the principal investigator, are judged to be clinically significant or potentially confound study results.

17. Pregnant or nursing mother.

18. Active alcohol or drug abuse or history of alcohol or drug abuse that, in the opinion of the principal investigator, might compromise subject safety, study safety assessments, or ability of subject to comply with study requirements.

19. Concurrent enrollment in another interventional study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)

Related Conditions & MeSH terms

• Staphylococcus Aureus

Intervention

Drug:
• Placebo
Placebo
• MEDI4893
Human immunoglobulin G1 kappa monoclonal antibody

Locations

Country	Name	City	State
United States	Research Site	Miami	Florida

Sponsors (1)

Lead Sponsor	Collaborator
MedImmune LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The occurence of adverse events and serious adverse events.		From the time of informed consent through 360 days post dose	Yes
Primary	Vital Sign Measurements	blood pressure, heart rate, respiratory rate, temperature	Pre-dose through Study Day 15	Yes
Primary	Clinical Safety lab measurements	Chemistry, Hematology and urinalysis	from Day 1 (pre-dose) through 90 days post dose	Yes
Secondary	Pharmacokinetic Assessments - Serum	MEDI4893 Pharmacokinetic parameters.	Pre-dose through 360 days post dose	Yes
Secondary	Anti Drug Antibody (ADA) Assessments - Serum	ADA responses to MEDI4893.	Pre-dose through 360 days post dose	Yes